---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-006994"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:14:13.722695+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Climb Bio updates on budoprutug and CLYM116 trials; cash runway into 2028

## Summary
- First patient dosed in PrisMN Phase 2 trial of budoprutug for primary membranous nephropathy (Nov 2025).
- Received China IND clearance for budoprutug in SLE; parallel China Phase 1b to enroll lupus nephritis patients (Dec 2025).
- Completed dosing of first cohort in Phase 1 trial of subcutaneous budoprutug and of CLYM116 in healthy volunteers (Dec 2025).
- Expects initial data from SC budoprutug Phase 1 (H1 2026), budoprutug pMN Phase 2 (H2 2026), and CLYM116 Phase 1 (mid-2026).
- Cash, cash equivalents, and marketable securities expected to fund operations into 2028.

## SEC filing metadata
- accession: 0001193125-26-006994
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312526006994/0001193125-26-006994-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312526006994/d92848d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-006994
- JSON: https://secwatch.observer/filing/0001193125-26-006994.json
- Plain text: https://secwatch.observer/filing/0001193125-26-006994.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.